[go: up one dir, main page]

WO2006016602A1 - Préparation contenant du natéglinide dont l'amertume a été réduite - Google Patents

Préparation contenant du natéglinide dont l'amertume a été réduite Download PDF

Info

Publication number
WO2006016602A1
WO2006016602A1 PCT/JP2005/014647 JP2005014647W WO2006016602A1 WO 2006016602 A1 WO2006016602 A1 WO 2006016602A1 JP 2005014647 W JP2005014647 W JP 2005014647W WO 2006016602 A1 WO2006016602 A1 WO 2006016602A1
Authority
WO
WIPO (PCT)
Prior art keywords
nateglinide
weight
oral solid
water
solid preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2005/014647
Other languages
English (en)
Japanese (ja)
Inventor
Kunikazu Suzuki
Wataru Wakui
Akira Yabuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to KR1020127034106A priority Critical patent/KR20130018956A/ko
Priority to JP2006531680A priority patent/JP5551852B2/ja
Publication of WO2006016602A1 publication Critical patent/WO2006016602A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to an oral solid preparation of nateglinide useful as a diabetic drug.
  • Nateglinide [Compound name: N— (Trans-4 isopropyl cyclohexyl carbo- ol) -D-Fu-lualanin] (Japanese Patent Publication No. 4-15221) is rapidly administered by oral administration before meals. It has an excellent effect of being absorbed into blood and improving postprandial hyperglycemia (fast-acting, short-acting type), and is actually used in clinical settings as a treatment for diabetes.
  • nateglinide drug substance itself has a very strong bitter taste, when used as an oral preparation, it was necessary to reduce the bitter taste by coating the surface of the tablet.
  • Nateglinide is an excellent drug to improve postprandial hyperglycemia and therefore requires pre-meal administration.
  • conventional preparations require water intake at the same time as the drug at the time of administration, and nateglinide-containing preparations that do not require water at the time of intake have been required.
  • oral preparations that do not require water when taken have been developed for oral preparations.
  • a formulation called an intraoral (fast) disintegrating tablet is known which is disintegrated in the oral cavity and then absorbed in the digestive tract!
  • nateglinide drug substance has a very strong bitter taste as described above, when an orally disintegrating tablet is produced by the usual method, it has a bitter taste in the oral cavity at the time of taking it, giving the user unpleasantness and practical use.
  • Patent Documents 2 to 6 there are several known powers of preparations containing nateglinide so far that have solved the above problems.
  • Patent Document 1 Japanese Patent Publication No. 4 15221
  • Patent Document 2 WO98Z22105
  • Patent Document 3 WOO 1/21159
  • Patent Document 4 WO0lZ47557 0
  • An object of the present invention is to provide a nateglinide-containing oral solid preparation that does not give a bitter taste and maintains the fast-acting short-term properties of nateglinide.
  • the present invention is an oral solid preparation containing nateglinide and a water-soluble polymer, characterized by containing 0.3 to 6 parts by weight of the water-soluble polymer in terms of solid content with respect to 1 part by weight of nateglinide.
  • the oral solid preparation is provided.
  • the present invention also relates to an oral solid preparation with reduced bitterness containing nateglinide and a water-soluble polymer, comprising 0.3 to 6 parts by weight of the water-soluble polymer in terms of solid content per 1 part by weight of nateglinide.
  • the oral solid preparation is provided.
  • the present invention is also an oral solid preparation containing nateglinide and a water-soluble polymer, comprising a step of dissolving nateglinide and a water-soluble polymer in an organic solvent, and a step of forming a granular substance from the obtained solution!
  • a method for producing an oral solid preparation with reduced bitterness is also provided.
  • nateglinide which is a diabetic drug
  • Nateglinide contained in the oral solid preparation of the present invention can be synthesized according to the method described in Japanese Patent Publication No. 4-15221.
  • the crystal form used is not particularly limited. Force H type or B type is preferred. H type is particularly preferred from the viewpoint of stability.
  • the water-soluble polymer contained in the oral solid preparation of the present invention is a polymer having a weight average molecular weight of preferably about 1,000 to about 2 million, more preferably about 10,000 to about 200,000, and at 25 ° C.
  • the solubility in water or any aqueous medium such as an aqueous solution showing acidity or alkalinity is preferably 0.1 lgZlOOmL or more.
  • methylcellulose and hydroxypropyl pill cellulose described in the Japanese Pharmacopoeia or the US Pharmacopoeia including 53.4-77.5% of hydroxypropoxyl group when dry product is quantified
  • hydroxypropyl methylcelluloses (For example, hydroxypropyl methyl senol p-ace 2208, 2906, 2910), positive bi-redo, n (f column; t is p-bi-no-redo, N K2 5, K30, ⁇ 90, etc.), copolydon, polybulu alcohol , Aminoalkyl metaatreate copolymer, polyburacetal jetylaminoacetate, etc., preferably methinoresenorelose, hydroxypropinoresenorelose, hydroxypropinoremethinoresenolate 2910 .
  • the amount of the water-soluble polymer added is 0.3 to 6 parts by weight, preferably 0.5 to 3 parts by weight, in terms of solid content, per 1 part by weight of nateglinide.
  • Disintegrants include sodium carboxymethyl starch, carmellose, carmellose sodium, carmellose calcium, croscarmellose sodium, crospovidone, low-substituted hydroxypropylcellulose (5. 0 to 16.0% included (see Japanese Pharmacopoeia 13th revision D— 885 to D—888), partially alpha-ized starch, etc., with crospovidone, carmellose and croscarmellose sodium being particularly preferred.
  • the amount of the disintegrant added is preferably 0.01 to 16 parts by weight, and preferably 0.1 to 4 parts by weight with respect to 1 part by weight of nateglinide.
  • the oral solid preparation of the present invention is preferably in the form of an orally disintegrating tablet.
  • additives used in normal oral preparations can be used as other ingredients, and although not particularly limited, sugars, starches, crystalline cell mouths and the like are added.
  • excipients; binder; a lubricant, such as magnesium stearate, talc; P H adjusting agent; Coloring agents; flavoring agents such as saccharides and menthol can be blended.
  • an oral solid preparation with reduced bitterness it can be produced by using a conventional method.
  • a mixture or granulated product of nateglinide and a water-soluble polymer is used as a tablet, capsule or It can be provided as a formulation such as granules or powders.
  • the oral solid preparation of the present invention is provided as a tablet, it is provided as a tablet by optionally adding a disintegrant or other additives to a mixture or granulated product of nateglinide and a water-soluble polymer and then compressing the tablet. it can.
  • the powder obtained by mixing the composition with an appropriate mixer can be produced by tableting, or can be produced by dry granulation (such as compaction granulation) or wet granulation (fluidized bed). (Granulation method, agitation granulation method, extrusion granulation method, etc.) or a spray-drying method, etc., and a granulated product is prepared. Can be manufactured by locking.
  • nateglinide and the water-soluble polymer used in the present invention are usually dissolved in a suitable organic solvent.
  • a layer is formed by coating core particles composed of a disintegrant or the like with a solution in which nateglinide and a water-soluble polymer are dissolved in an organic solvent together with other components as necessary.
  • the granular material can be obtained as a granulated product.
  • core particles containing excipients such as crystalline cellulose are coated with nateglinide to form an inner layer of nateglinide, and the resulting granular material is further combined with other components as necessary.
  • An outer layer is formed by coating with a water-soluble polymer that can be used in the present invention, and finally a granular material can be obtained as a granulated product.
  • nateglinide and the water-soluble polymer used in the present invention are usually dissolved in a suitable organic solvent.
  • the organic solvent the same solvents as described for the wet granulation method can be used.
  • tableting when producing orally disintegrating tablets, it is preferable to tablet at low pressure, preferably 50 NZm 2 or less.
  • the tablets can be film-coated as necessary.
  • Film co For example, hydroxypropylmethylcellulose 2910 can be used as the tempering agent.
  • the oral solid preparation of the present invention is provided as a granule or powder
  • the dry granulation method is also used.
  • Compressed granulation method, etc. or wet granulation method (fluidized bed granulation method, stirring granulation method, extrusion granulation method, etc.) or a normal granulation method such as spray-drying production method. .
  • the oral solid preparation of the present invention produced by these methods can be ingested without the need for water compared to conventional preparations, has reduced bitterness when disintegrated in the oral cavity, and is compared with the current nateglinide tablets. It is a preparation that can ensure bioequivalence in in vitro evaluation.
  • the oral solid preparation of the present invention in particular, in the form of a powder containing 1 part by weight of aminoalkyl methacrylate copolymer E in terms of solid content with respect to 1 part by weight of nateglinide.
  • the oral solid preparation in the form of a powder containing 1 part by weight of aminoalkyl methacrylate copolymer E in terms of solid content with respect to 1 part by weight of nateglinide.
  • Oral solid preparations in the form of a powder containing are also preferred.
  • the oral solid preparation in which the outer layer is composed of 2 parts by weight of hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose or polybutylpyrrolidone in terms of solid content with respect to 1 part by weight of nateglinide is particularly preferred.
  • oral solid preparations which are also composed of 1 part by weight of hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose or polyvinylpyrrolidone in terms of conversion.
  • an oral solid preparation in the form of granules containing a crystalline cellulose core, an inner layer of nateglinide, and an outer layer of 0.7 parts by weight of aminoalkyl methacrylate copolymer E in terms of solid content with respect to 1 part by weight of nateglinide. Also preferred.
  • nateglinide orally in the form of a tablet, containing 1.1 parts by weight of methylcellulose and croscarmellose sodium in terms of solid content with respect to 1 part by weight of nateglinide, and having a hardness of 20-30 N / m 2
  • Solid formulations are also preferred where oral solid formulations with 1 part by weight methylcellulose and 0.1 parts by weight croscarmellose sodium are more preferred Among these, an oral solid preparation in which nateglinide is dispersed in a water-soluble polymer is preferable.
  • an oral solid preparation for example, it is preferable to use a solvent removal method in which nateglinide and a water-soluble polymer are dissolved in an organic solvent and then the solvent is removed.
  • An oral solid preparation with reduced bitterness containing nateglinide and a water-soluble polymer comprising the steps of dissolving nateglinide and a water-soluble polymer in an organic solvent and forming a particulate material from the resulting solution (e.g. spray drying).
  • the method of manufacturing is preferred U ⁇ .
  • the average particle size of the particles is preferably 0.05 to 0.85 mm.
  • the oral solid preparation of the present invention is in the form of an orally disintegrating tablet, its hardness is preferably 50 NZm 2 or less, more preferably 20 to 30 NZm 2 .
  • the oral solid preparation of the present invention is preferably a preparation that is rapidly disintegrated by saliva in the oral cavity and can be swallowed as it is. But of course it can be taken with water. It is desirable that the preparation of the present invention disintegrates within 60 seconds when placed in the oral cavity.
  • Nateglinide and the water-soluble polymer shown in Table 1 were mixed thoroughly in a 1: 1 ratio, and nateglinide-containing powder preparation was obtained by crushing with a crushing granulator (Roller 1 Compactor 1 and Turbo Industries).
  • a crushing granulator Roller 1 Compactor 1 and Turbo Industries.
  • Water-soluble polymers listed in Table 4 are fluidized-bed granulator (FLO— 1) on the core particles layered by spraying ethanol aqueous solution of nateglinide onto spherical core particles of crystalline cellulose (Selfia CP507, Asahi Kasei Co., Ltd.). Type, Freund Sangyo Co., Ltd.) to obtain nategrid-containing film-coated granules.
  • FLO— 1 fluidized-bed granulator
  • Taste evaluation by sensory evaluation was performed on the powder formulations obtained in Examples 1 to 17 above. Evaluation was conducted by dissolving a preparation corresponding to 10 mg of nateglinide in the oral cavity to evaluate the taste. In addition, the evaluation was performed in five stages. Table 5 shows the evaluation criteria, and Tables 2 to 4 show the taste evaluation results.
  • Copolidon (trade name Copoli A A64, BASF3 ⁇ 4
  • the amount of each ⁇ added indicates weight ⁇ .
  • the water-soluble polymers are as shown in Table 2 footnotes.
  • the formulation of the present invention provides an oral solid formulation containing nateglinide with low bitterness.
  • the strength and bitterness specific to nateglinide could be reduced by dispersing nateglinide in the water-soluble polymer.
  • a solution of nateglinide and the polymer shown in Table 6 dissolved in an organic solvent (dichloromethane Z ethanol 6: 4) was prepared using the fluidized bed granulator (FLO-1 type, Freund Corporation) as shown in Table 6. It was sprayed in the fluidized bed to the powder described in the addition part at the time of granulation to obtain a granulated product. Additives described in the post-addition part were added to the resulting granulated product, and nateglinide-containing orally disintegrating tablet preparations were obtained by low-pressure tableting.
  • V ro evaluation (dissolution test) is evaluated with J P 1 'J P 2 test solution described in Japanese Pharmacopoeia
  • nateglinide (“Fastic” 90 mg tablet) that is currently on the market was dissolved in the oral cavity and taste evaluation was performed. As a result of the evaluation, the bitterness was very strong, so the tablet was discharged on the way. The aftertaste also remained for several hours.
  • the bitterness was 1, the presence or absence of aftertaste: 3, the aftertaste: 1, and the total: 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une préparation perorale à action rapide et de courte durée qui ne donne pas de sensation d'amertume et qui retient les propriétés du natéglinide. La préparation perorale solide, dont l'amertume a été réduite, contient du natéglinide et un polymère soluble dans l'eau, est caractérisée en ce qu'elle contient le polymère soluble dans l'eau dans une proportion de 0,3 à 6 parties par poids, en terme de quantité solide, par partie par poids du natéglinide.
PCT/JP2005/014647 2004-08-10 2005-08-10 Préparation contenant du natéglinide dont l'amertume a été réduite Ceased WO2006016602A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020127034106A KR20130018956A (ko) 2004-08-10 2005-08-10 쓴맛이 감소된 나테글리니드 함유 제제
JP2006531680A JP5551852B2 (ja) 2004-08-10 2005-08-10 苦味の低減したナテグリニド含有製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-233797 2004-08-10
JP2004233797 2004-08-10

Publications (1)

Publication Number Publication Date
WO2006016602A1 true WO2006016602A1 (fr) 2006-02-16

Family

ID=35839371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/014647 Ceased WO2006016602A1 (fr) 2004-08-10 2005-08-10 Préparation contenant du natéglinide dont l'amertume a été réduite

Country Status (3)

Country Link
JP (2) JP5551852B2 (fr)
KR (2) KR20070040389A (fr)
WO (1) WO2006016602A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013127009A (ja) * 2006-08-08 2013-06-27 Kissei Pharmaceutical Co Ltd 苦味をマスキングした口腔内崩壊錠、およびその製造方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS519712B2 (fr) * 1972-12-29 1976-03-29
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JP2001019639A (ja) * 1999-07-07 2001-01-23 Nitto Yakuhin Kogyo Kk 感冒固形製剤
JP2001518490A (ja) * 1997-10-03 2001-10-16 エラン コーポレーシヨン ピーエルシー 味遮蔽された製剤
WO2002034254A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Preparations contenant du nateglinide
JP2002179558A (ja) * 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 固形製剤
WO2003026697A2 (fr) * 2001-09-26 2003-04-03 Pharmacia Corporation Compositions a desintegration orale, acceptables sur le plan organoleptique
JP2004010611A (ja) * 2002-06-06 2004-01-15 Nisshin Yakuhin Kogyo Kk マスキング組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58401B2 (ja) * 1974-07-15 1983-01-06 明治製菓株式会社 ケイコウヨウイヤクヒンソセイブツノ セイホウ
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
WO2001047557A1 (fr) * 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Preparations orales pour diabetes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS519712B2 (fr) * 1972-12-29 1976-03-29
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JP2001518490A (ja) * 1997-10-03 2001-10-16 エラン コーポレーシヨン ピーエルシー 味遮蔽された製剤
JP2001019639A (ja) * 1999-07-07 2001-01-23 Nitto Yakuhin Kogyo Kk 感冒固形製剤
JP2002179558A (ja) * 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 固形製剤
WO2002034254A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Preparations contenant du nateglinide
WO2003026697A2 (fr) * 2001-09-26 2003-04-03 Pharmacia Corporation Compositions a desintegration orale, acceptables sur le plan organoleptique
JP2004010611A (ja) * 2002-06-06 2004-01-15 Nisshin Yakuhin Kogyo Kk マスキング組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013127009A (ja) * 2006-08-08 2013-06-27 Kissei Pharmaceutical Co Ltd 苦味をマスキングした口腔内崩壊錠、およびその製造方法
JP5237098B2 (ja) * 2006-08-08 2013-07-17 キッセイ薬品工業株式会社 苦味をマスキングした口腔内崩壊錠、およびその製造方法

Also Published As

Publication number Publication date
JP5551852B2 (ja) 2014-07-16
KR20130018956A (ko) 2013-02-25
KR20070040389A (ko) 2007-04-16
JP2012121911A (ja) 2012-06-28
JPWO2006016602A1 (ja) 2008-05-01
JP5578492B2 (ja) 2014-08-27

Similar Documents

Publication Publication Date Title
EP2893940B1 (fr) Matière granulée pour un comprimé qui se désintègre rapidement dans la bouche
EP1985310B1 (fr) Formes de dosage solide
CN101868228B (zh) 口腔内崩解片
CN101466359B (zh) 快速释放的对乙酰氨基酚片
US7732492B2 (en) Nateglinide-containing preparation
WO2010104170A1 (fr) Comprimé et poudre granulée contenant du 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
CA2688721A1 (fr) Formulation pharmaceutique stable pour un inhibiteur de la dpp-4
CN101983054A (zh) 含有咪达那新的口腔内迅速崩解性片剂
JPWO2009101940A1 (ja) 溶出性の改善された錠剤
JP6479658B2 (ja) 超速崩壊錠剤及びその製造方法
CN103251594B (zh) 瑞格列奈二甲双胍的片剂
CN1352558B (zh) 即释型口服用药物组合物
WO2006115770A2 (fr) Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale
JP2010001242A (ja) レバミピド固形製剤及びその製造方法
JP5578492B2 (ja) 苦味の低減したナテグリニド含有製剤
JP2005139086A (ja) 速崩壊製剤
JP6328138B2 (ja) Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
JP5201837B2 (ja) 口腔内速崩壊錠
CN110913843B (zh) 药物组合物
JP2022072050A (ja) エドキサバンを含有する口腔内崩壊錠
WO2006047067A1 (fr) Comprimes comprenant un agent actif faiblement compressible et succinate de tocopherol polyethyleneglycol (tpgs)
JPWO2003075918A1 (ja) 塩酸ピルジカイニド含有錠剤（湿式）
TW201609193A (zh) 含有碳酸鹽之口腔內崩解錠劑用組成物及口腔內崩解錠劑
JP2000344664A (ja) ビタミンｋを含有する口腔内崩壊型錠剤
HK1207988B (en) Granulated material for tablet that rapidly disintegrates in mouth

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006531680

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020077003164

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase